Murakami, Naoka http://orcid.org/0000-0001-8168-5811
Hayden, Robert
Hills, Thomas http://orcid.org/0000-0003-0322-5822
Al-Samkari, Hanny http://orcid.org/0000-0001-6175-1383
Casey, Jonathan
Del Sorbo, Lorenzo
Lawler, Patrick R.
Sise, Meghan
Leaf, David E. http://orcid.org/0000-0001-7875-090X
Article History
First Online: 17 February 2023
Competing interests
: H.A.-S. disclosures include consultancy (Agios, Dova/Sobi, argenx, Rigel, Novartis, Forma, Moderna) and research funding (Agios, Dova/Sobi, Amgen). P.R.L. is an investigator in the REMAP-CAP ACE2 RAS Domain, which is investigating renin–angiotensin–system-modulating treatments for COVID-19; is supported by a Heart and Stroke Foundation of Canada National New Investigator Award; and has received consulting honoraria from Novartis, CorEvitas and Brigham and Women’s Hospital (Boston, MA, USA), as well as royalties from McGraw-Hill Publishing. L.D.S. is inventor of a patent licensed to SQI Diagnostic and has received research funding from the Canadian Institutes of Health Research. M.E.S. has received research funding from Gilead Sciences awarded to her institution; additional disclosures include research funding from AbbVie, Merck, EMD-Serono and Angion and service as a scientific advisory board member for Travere and Mallinckrodt. The other authors declare no competing interests.
Free to read: This content has been made available to all.